Brokerages Set Palvella Therapeutics, Inc. (NASDAQ:PVLA) Target Price at $199.53

Palvella Therapeutics, Inc. (NASDAQ:PVLA) has received a consensus recommendation of “Moderate Buy” from the sixteen analysts that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, fourteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $199.5333.

PVLA has been the subject of a number of analyst reports. Stifel Nicolaus set a $250.00 price target on Palvella Therapeutics in a research report on Tuesday, February 24th. Chardan Capital reiterated a “buy” rating and issued a $240.00 price objective on shares of Palvella Therapeutics in a research report on Thursday, May 21st. BTIG Research increased their price objective on Palvella Therapeutics from $192.00 to $215.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Stephens reiterated an “overweight” rating and issued a $220.00 price objective on shares of Palvella Therapeutics in a research report on Thursday, May 21st. Finally, Wall Street Zen lowered Palvella Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th.

Insiders Place Their Bets

In related news, COO Kathleen Goin sold 4,302 shares of the stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $110.73, for a total value of $476,360.46. Following the completion of the transaction, the chief operating officer directly owned 2,154 shares in the company, valued at approximately $238,512.42. This represents a 66.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 17.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. KBC Group NV purchased a new position in Palvella Therapeutics in the first quarter worth approximately $28,000. Group One Trading LLC grew its position in Palvella Therapeutics by 151.5% in the fourth quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after acquiring an additional 200 shares during the period. Russell Investments Group Ltd. purchased a new position in Palvella Therapeutics in the third quarter worth approximately $36,000. JPMorgan Chase & Co. grew its position in Palvella Therapeutics by 108,066.7% in the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after acquiring an additional 3,242 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Palvella Therapeutics in the second quarter worth approximately $85,000. 40.11% of the stock is currently owned by hedge funds and other institutional investors.

Palvella Therapeutics Price Performance

PVLA stock opened at $118.84 on Thursday. The business has a 50 day simple moving average of $118.40 and a 200-day simple moving average of $109.24. The firm has a market capitalization of $1.70 billion, a PE ratio of -28.50 and a beta of -0.14. Palvella Therapeutics has a 1 year low of $20.35 and a 1 year high of $151.18.

Palvella Therapeutics (NASDAQ:PVLA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). On average, equities research analysts expect that Palvella Therapeutics will post -5.26 EPS for the current year.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.